Calcium channel blockers: the study of the assortment, socio-economic affordability and volumes of consumption in Ukraine

L. V. Iakovlieva, O. Ya. Mishchenko, V. Yu. Adonkina

Abstract


The results of analysis of the pharmaceutical market of calcium channel blockers (CCBs), assessment of their economic affordability and consumption volumes in Ukraine are given in the article. It has been found that within 2009-2013 at the pharmaceutical market of Ukraine there was the increase of the assortment of CCBs due to import generic drugs. Most drugs are highly affordable to the average citizen of Ukraine, it allows to select a drug taking into account its cost, efficiency and safety.During the study period the consumption of CCBs increased. The consumption of dihydropyridine drugs dominates; these drugs with a pronounced vasodilative effect are more effective. The lowest consumption volumes are typical for the least affordable drugs of nimodipine.


Keywords


arterial hypertension (AH); calcium channel blockers (CCBs); socio-economic affordability; adequacy of solvency; consumption; ATC/DDD-methodology

References


Вивчення споживання лікарських засобів за анатомо-терапевтично-хімічною класифікацією та встановленими добовими дозами (АТС/DDD – методологія) : метод. рек. / А. М. Морозов, Л. В. Яковлєва, А. В. Степаненко та ін. – Х.: Стиль-Издат, 2013. – 34 с.

Громовик Б. П. Фармацевтичний маркетинг: теоретичні та прикладні засади / Б. П. Громовик, Г. Д. Гасюк, О. Р. Левицька. – Вінниця: Нова Книга, 2004. – 464 с.

Довгун С. С. Оценка стоимости и экономической доступности ноотропных препаратов, назначаемых больным с инсультом / С. С. Довгун // Современные проблемы науки и образования. – 2012. – № 2. – С. 33-39.

Красницкий В. Б. Блокаторы медленных кальциевых каналов и их место в лечении артериальной гипертензии / В. Б. Красницкий // Медицина неотложных состояний. – 2007. – № 3 (10). – С. 39-44.

Марцевич С. Ю. Роль антагонистов кальция в современном лечении сердечно-сосудистых заболеваний / С. Ю. Марцевич // Русский медицинский журнал. – 2003. – № 11. – С. 539-541.

Мнушко З. М. Система забезпечення доступності лікарських засобів / З. М. Мнушко, І. В. Тіманюк // Вісник фармації. – 2007. – № 1 (49). – С. 52-57.

Постникова С. Л. Дигидропиридиновые блокаторы кальциевых каналов в лечении артериальной гипертензии / С. Л. Постникова // Русский медицинский журнал. – 2007. – № 6. – С. 556-559.

Jonsson B. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost–effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension / B. Jonsson, L. Hansson // J. Intern. Med. – 2003. – Vol. 253, № 4. – P. 472-480.

Law M. R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta–analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / M. R. Law, J. K. Morris, N. J. Wald // BMJ. – 2009. – Vol. 338, № 12. – P. 1245-253. – Режим доступу : http://www.bmj.com/highwire/section-pdf/8878/8/1. – Назва з екрану.

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenololadding bendroflumethiazide as required in the anglo–scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT–BPLA): a multicenter randomized controlled trial for ASCOT investigators / D. Dahlof, P. S. Sever, N. R. Poulter et al. // Lancet. – 2005. – Vol. 366, № 9489. – P. 895–906.

Salvetti A. Guidelines for antihypertensive treatment: an update after the ALLHAT Study / A. Salvetti, L. Ghiadoni // Journal of the American Society of Nephrology. – 2004. – Vol. 15, Suppl. 1. – P. S51–S54.


GOST Style Citations


1. Morozov AM, Yakovlieva LV, Stepanenko AV et al. Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDD – metodolohiia). Kharkiv: Stil-Izdat; 2013. 34 p.

2. Hromovyk BP, Hasiuk HD, Levytska OR. Farmatsevtychnyi marketynh: teoretychni ta prykladni zasady. Vinnytsia: Nova Knyha; 2004. 464 p.

3. Dovgun SS. Sovremennye problemy nauki i obrazovaniia. 2012;2:33–9.

4. Krasnickii VB. Medicina neotlozhnykh sostoianii. 2007;3(10):39–44.

5. Martcevich SJu. Russkii medicinskii zhurnal. 2003;11:539–41.

6. Mnushko ZM, Timaniuk IV. Visnyk farmatsii = News of Pharmacy. 2007;1(49):52–7.

7. Postnikova SL. Russkii medicinskii zhurnal. 2007;6:556–9.

8. Jonsson B, Hansson L. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost–effectiveness of intensive blood pressure lowering and low–dose aspirin in patients with hypertension. J. Intern. Med. 2003;253(4):472–80.

9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta–analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(12):1245–253. Available from: http://www.bmj.com/highwire/section-pdf/8878/8/1

10. Dahlof D, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the anglo–scandinavian cardiac outcomes trial–blood pressure lowering arm (ASCOT–BPLA): a multicenter randomized controlled trial for ASCOT investigators. Lancet. 2005;366(9489):895–906.

11. Salvetti A, Ghiadoni L. Guidelines for antihypertensive treatment: an update after the ALLHAT Study. Journal of the American Society of Nephrology. 2004;15(1):S51–S54.





DOI: https://doi.org/10.24959/sphhcj.15.3

Abbreviated key title: Soc. farm. ohor. zdor.

ISSN 2518-1564 (Online), ISSN 2413-6085 (Print)